| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt","company":"Spyre Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_80e422be71ad6d8a","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt","content_type":"text/plain","enriched_at":"2026-04-11T07:18:35.436095+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"syre-20260410","final_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt","source_event_id":"evt_b1d17b26df79","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"3cc12a16d08233d6","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-05-27","2026-04-02","2026-04-10","2026-04-11"],"entities":[{"asset_class":"equity","name":"Spyre Therapeutics, Inc.","relevance":"high","symbol":"SYRE","type":"issuer"},{"asset_class":"service_provider","name":"KPMG LLP","relevance":"medium","symbol":"","type":"auditor"},{"asset_class":"individual","name":"Cameron Turtle","relevance":"medium","symbol":"","type":"person"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal (no prior filing/version details included).","The specific names of the three Class I director nominees are not included in the provided text excerpt.","Details of executive compensation items and the amended/restated 2016 Employee Stock Purchase Plan terms are not included in the provided excerpt.","The SEC filing 'Amendment No.' value is shown as blank/unspecified in the excerpt ('(Amendment No. )')."],"key_facts":["Form type: DEF 14A (Schedule 14A Proxy Statement).","Issuer: Spyre Therapeutics, Inc. (SYRE).","Annual Meeting date: Wednesday, May 27, 2026.","Annual Meeting time: 12:00 p.m. Eastern Time.","Meeting format: virtual meeting conducted exclusively online via live audio webcast at www.virtualshareholdermeeting.com/SYRE2026.","Record Date: April 2, 2026 (stockholders of record at close of business entitled to notice and vote).","Purposes of the Annual Meeting include: (1) elect three Class I director nominees to serve until the 2029 Annual Meeting; (2) non-binding advisory approval of named executive officer compensation; (3) ratify KPMG LLP as independent registered public accounting firm for year ending December 31, 2026; (4) approve amended and restated 2016 Employee Stock Purchase Plan; (5) transact other matters properly brought before the meeting.","Proxy statement is dated April 10, 2026 and signed by Cameron Turtle, Chief Executive Officer and Director.","The proxy materials (Proxy Statement and Annual Report for year ended December 31, 2025) are available at www.proxyvote.com."],"numeric_claims":[{"label":"Annual Meeting date","value":"2026-05-27"},{"label":"Annual Meeting time (ET)","value":"12:00 p.m."},{"label":"Record Date","value":"2026-04-02"},{"label":"Proxy statement date","value":"2026-04-10"},{"label":"Independent auditor year ending","value":"2026-12-31"}],"primary_claim":"Spyre Therapeutics, Inc. filed Form DEF 14A (proxy statement) for its 2026 Annual Meeting of Stockholders to be held on May 27, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Spyre Therapeutics, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing sets the meeting date, virtual format, record date, and lists the matters to be voted on.","topics":["SEC filing","proxy statement","annual meeting","board of directors","executive compensation","independent auditor ratification","employee stock purchase plan","virtual meeting","record date"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Spyre Therapeutics, Inc. \u00b7 Filed 20260410","ticker":"SYRE","tickers":["SYRE"],"title":"SYRE filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000039.txt"}... |